Quick Answer
Lineage Cell Therapeutics, Inc. reported Total Assets of $112.58 million for fiscal year 2025.
Lineage Cell Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $112.58M | -0.6% |
| 2024 | $113.22M | +12.1% |
| 2023 | $101.02M | -18.3% |
| 2022 | $123.66M | -29.2% |
| 2021 | $174.54M | +61.7% |
| 2020 | $107.95M | -14.0% |
| 2019 | $125.48M | +23.4% |
| 2018 | $101.66M | -41.3% |
| 2017 | $173.24M | +21.5% |
| 2016 | $142.57M | +50.6% |
| 2015 | $94.66M | +26.4% |
| 2014 | $74.90M | +29.7% |
| 2013 | $57.73M | +94.1% |
| 2012 | $29.75M | -35.1% |
| 2011 | $45.83M | -14.0% |
| 2010 | $53.27M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $89.64M | -7.2% | -1.3% |
| June 30, 2025 | $90.80M | -11.7% | -18.8% |
| March 31, 2025 | $111.75M | +3.0% | -1.3% |
| December 31, 2024 | $113.22M | +12.1% | +17.2% |
| September 30, 2024 | $96.59M | -9.0% | -6.0% |
| June 30, 2024 | $102.80M | -8.0% | -5.2% |
| March 31, 2024 | $108.48M | -4.2% | +7.4% |
| December 31, 2023 | $101.02M | -18.3% | -4.8% |
- Lineage Cell Therapeutics, Inc. showed a decrease of -0.6% in Total Assets compared to the prior fiscal year.
- Over the 2010–2025 period, Lineage Cell Therapeutics, Inc.’s total assets has grown by 111.3% (from $53.27 million to $112.58 million).
- The most recent figure is from Lineage Cell Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: